克里唑替尼一线医治肺癌确实好于放化疗吗？ 。
摘 要：孟加拉国碧康克唑替尼。
英国《临床肿瘤学杂志》2022年5月16日线上先给对一项克里唑替尼一线医治与一线有机化学治疗法相比较研究的总生活的最后剖析：来源于PROFILE 1014实验的結果BenjaminJ. Solomon, Dong-Wan Kim, Yi-Long Wu,Kazuhiko Nakagawa, Tarek Mekhail,EnriquetaFelip...Show More目地PROFILE 1014是一项III期临床试验，在晚后期内转性淋巴肿瘤蛋白激酶（ALK）呈阳性的非鳞非小细胞肺癌病患者中对克里唑替尼一线医治与一线有机化学治疗法开展了较为。在这里，大家对总存活（OS）的最后結果给予汇报。病患者与办法对病患者随机分组，一组内服克里唑替尼250mg，每日2次（n=172），另一组静脉血管给与培美曲塞500mg/m2 顺铂75mg/m2或卡铂（浓度值时间曲线下总面积5-6mg·mL/min），每3周一个疗程，数最多6个治疗过程（n=171）。恶性肿瘤进度后容许交叉式到克里唑替尼组。选用一种分层次多数秩检测和一种预设保秩构造无效時间实体模型表述交叉式
效用，对总存活开展剖析。結果对2组总生活的负相关随诊時间大概为46个月，有机化学治疗法组，144名（84.2%）病患者在之后的诊治中接纳了克里唑替尼。总生活的风险之比0.760（95%CI，0.548-1.053；双尾P=0.0978）。克里唑替尼组并未到负相关总存活時间（NR），有机化学治疗法组负相关总存活時间为47.5个月（95%CI，32.2个月至NR）。克里唑替尼组4年存活几率为56.6%（95%CI，48.3%-64.1%），有机化学治疗法组49.1%（95%CI，40.5%-57.1%）。对交叉式效用校准后，说明克里唑替尼组总存活有改进（风险比，0.346；95%自举CI，0.081-0.718）。在克里唑替尼医治且接着进行了ALK酪氨酸激酶受体的病患者中，观查到最多的总存活時间。沒有发觉新的安全性特点(过虑词)。结果PROFILE 1014科学研究的最后剖析为ALK重新排列的非小细胞肺癌病患者的总存活带来了新的标准，突显了克里唑替尼对提升这类病患者存活时长的益处。《壹篇》南南和晨晨Final Overall Survival Analysis Froma Study Comparing First-Line Crizotinib With Chemotherapy: Results From PROFILE1014 Benjamin J.Solomon, Dong-Wan Kim,Yi-Long Wu, KazuhikoNakagawa, Tarek Mekhail,Enriqueta Felip...Show MorePurposeThe phase III PROFILE 1014 trial compared crizotinib withchemotherapy as first-line treatment in patients with anaplastic lymphomakinase (ALK) –positive advanced nonsquamous non–small-cell lung cancer. Here,we report the 
final overall survival (OS) results.Patients andMethodsPatients were randomly assigned to receive oralcrizotinib 250 mg twice daily (n = 172) or intravenous pemetrexed 500 mg/m2 plus cisplatin 75mg/m2 or carboplatin(area under the concentration–time curve of 5 to 6 mg·mL/min) every 3 weeks fora maximum of six cycles (n = 171). Crossover to crizotinib was permitted afterdisease progression. OS was analyzed using a stratified log-rank test and aprespecified rank-preserving structural failure time model to account forcrossover.ResultsMedian follow-up duration for OS was approximately 46months for both arms. In the chemotherapy arm, 144 patients (84.2%) receivedcrizotinib in subsequent lines. Hazard ratio for OS was 0.760 (95% CI, 0.548 to1.053; two-sided P = .0978). Median OS was not reached (NR) withcrizotinib (95% CI, 45.8 months to NR) and 47.5 months with chemotherapy (95%CI, 32.2 months to NR). Survival probability at 4 years was 56.6% (95% CI,48.3% to 64.1%) with crizotinib and 49.1% (95% CI, 40.5% to 57.1%) with chemotherapy.After crossover adjustment, there was an improvement in OS that favoredcrizotinib (hazard ratio, 0.346; 95% bootstrap CI, 0.081 to 0.718). The longestOS was observed in crizotinib-treated patients who received a subsequent ALKtyrosine kinase inhibitor. No new safety signals were identified.ConclusionThe final analysis of the PROFILE 1014 study provides anew benchmark for OS in patients with ALK-rearranged non–small-cell lungcancer and highlights the benefit of crizotinib for prolonging survival in thispatient population.《壹篇》（与【微信号码：yaodaoyaofang】【微信号码：yaodaoyaofang】“桓兴医讯”同歩）系关键朝向医护人员的服务性【微信号码：yaodaoyaofang】，不因盈利为目地，不开展一切有偿服务和免费服务咨询，不销售一切商品，与ASCO、CSCO等全部技术专业学好和组织并没有任何的关联和联络，都不意味着一切官方网学好发音。热烈欢迎转截，以让大量的技术专业技术人员掌握医科学研究最前沿进度。文章照片均来源于互联网，不做商业行为，若有著作权异议请与《壹篇》联络。不断关注点赞——【手机微信：india2080】、称赞和分享——【手机微信：india2080】是一种心态和适用。药道网给予近期的药物新闻资讯，聚集 印度的全世界海淘药店：克唑替尼多少钱一个月。
